Floatz logo

Copanlisib

Advanced or Metastatic Solid Tumor

BayerSmall moleculePhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Advanced or Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Futibatinib
Taiho Pharmaceutical Co., Ltd.
Phase 2CCC
Inno-206
Bayer
Phase 1CC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Bayer
Phase 1CC
PREDNISONE TABLETS
Bayer
Phase 1CC
Rogaratinib
Bayer
Phase 1CC

View all 27 →

Same molecule, other indications

Copanlisib is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →